Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States
GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced approval of a clinical patent for arfolitixorin in the United States. The patent expires in 2038 and is a divisional patent for the master patent granted in the US in May 2019. The now granted patent (US 10,639,311) is more specifically focused on the dose regimen used in the ongoing clinical AGENT study.This regime has shown superior effectiveness of reducing tumor growth compared to leucovorin and 5-fluorouracil. This better effect is due to a stronger inhibition